IMAX CEO says 'The Odyssey' box office 'more extreme' than expected; addresses sale rumors

What happened

IMAX CEO Rich Gelfond stated that the opening weekend performance of 'The Odyssey' was 'more extreme' than anticipated, with the film grossing $264.1 million globally and IMAX capturing over 20% of those sales. This underscores IMAX's continued leverage to major tentpole releases, though the company's valuation already reflects such blockbuster success. Gelfond also addressed recent sale rumors, though specifics were not disclosed in the article. The strong start to 2026 supports near-term bullish sentiment, but the DeepValue report maintains a cautious stance given the cyclical nature of box office revenue and limited long-term TAM. The report rates IMAX a Potential Sell with a base case of $34, implying limited upside from current levels around $35.

Implication

Investors should view the 'Odyssey' outperformance as a positive data point but not a catalyst to chase the stock. The DeepValue report highlights that IMAX trades at ~48x trailing EPS and ~18x EV/EBITDA, prices that already assume near-perfect slate execution. Any shortfall versus the $1.4B 2026 box office target — even with this strong start — would compress the multiple. The internal multiplex TAM of ~3,600 locations, already 48% penetrated, caps unit growth, and China regulatory risks persist. With the stock near the top of its base-to-bear range (~$24-$45), the margin of safety is thin; trimming into strength remains the prudent move.

Thesis delta

The news does not change the core thesis that IMAX is overvalued based on repeatable through-cycle earnings. However, the 'Odyssey' performance provides a near-term tailwind that may delay the thesis's bear-case realization. The implied risk/reward remains unfavorable, with the stock already pricing in this positive outcome.